Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02101905 |
|
Recruitment Status :
Active, not recruiting
First Posted : April 2, 2014
Last Update Posted : April 29, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anaplastic Astrocytoma Anaplastic Ependymoma Anaplastic Oligodendroglioma Gliosarcoma Mixed Glioma Recurrent Adult Brain Neoplasm Recurrent Glioblastoma | Other: Laboratory Biomarker Analysis Drug: Lapatinib Drug: Lapatinib Ditosylate Other: Pharmacological Study Procedure: Therapeutic Conventional Surgery | Phase 1 |
PRIMARY OBJECTIVES:
I. To achieve an intratumoral lapatinib (lapatinib ditosylate) concentration of at least 1.5 uM in at least 70% of patients 3 hours after the last dose of pulsatile lapatinib. (Group A) II. To determine the pharmacodynamic (PD) effect of pulsatile lapatinib (at pulsatile maximum tolerated dose [MTD]) on epidermal growth factor receptor (EGFR) phosphorylation (using Mesoscale Discovery enzyme-linked immunosorbent assay [ELISA] assay for total and phospho-EGFR). (Group A and Reference Group)
SECONDARY/EXPLORATORY OBJECTIVES:
Ia. To evaluate the safety profile of pulsatile lapatinib in pre-operative patients with EGFR amplified recurrent high-grade glioma. (Group A and Reference Group) Ib. To evaluate acute and late toxicities associated with pulsatile lapatinib. (Group A and Reference Group) II. To determine the effect of lapatinib on tumor cell proliferation (marker of proliferation Ki-67 [KI-67] staining). (Group A compared to Reference Group) III. To determine the ex-vivo sensitivity of tumor sphere cultures to lapatinib. (Group A and Reference Group) IV. To assess tumor objective response rate (ORR). (Group A and Reference Group) V. To estimate overall survival (OS). (Group A and Reference Group) VI. To estimate progression-free survival. (Group A and Reference Group)
OUTLINE: Patients are assigned to 1 of 2 treatment groups.
GROUP A: Patients receive lapatinib ditosylate orally (PO) twice daily (BID) on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
REFERENCE GROUP: Patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for at 30 days, every 2 months for 2 years, and every 6 months thereafter.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 29 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma |
| Actual Study Start Date : | March 13, 2014 |
| Actual Primary Completion Date : | October 19, 2021 |
| Estimated Study Completion Date : | October 19, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Group A (lapatinib ditosylate, surgery)
Patients receive lapatinib ditosylate PO BID on days -2 to 0. Within 3-5 hours after last dose of lapatinib ditosylate, patients undergo surgical resection of tumor on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Other: Laboratory Biomarker Analysis
Correlative studies Drug: Lapatinib Given PO
Other Names:
Drug: Lapatinib Ditosylate Given PO
Other Name: Tykerb Other: Pharmacological Study Correlative studies Procedure: Therapeutic Conventional Surgery Undergo surgical resection of tumor |
|
Active Comparator: Reference Group (surgery, lapatinib ditosylate)
Patients undergo surgery on day 0. Within 30 days of surgical resection of tumor, patients receive lapatinib ditosylate BID for 2 days every 7 days. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Other: Laboratory Biomarker Analysis
Correlative studies Drug: Lapatinib Given PO
Other Names:
Drug: Lapatinib Ditosylate Given PO
Other Name: Tykerb Other: Pharmacological Study Correlative studies Procedure: Therapeutic Conventional Surgery Undergo surgical resection of tumor |
- To Determine the Lapatinib Ditosylate Intratumoral Concentration (Pharmacokinetics) [ Time Frame: Baseline and day of surgery ]4 pk samples obtained: pretreatment, pre-surgery, post-surgery and interpolated pre-surgery each subject received 2500mg twice a day for two days.
- To Determine the Ratio of Phosphorylated (p)EGFR/Total EGFR (PD) in Tumor Tissue [ Time Frame: Day of surgery ]A ratio of pEGFR/total EGFR at 80% reduction from a median value from the untreated reference group will be considered as the putative threshold to qualify a near complete inhibition of EGFR (at 80%).
- Incidence of Adverse Events (AEs) [ Time Frame: Up to day 30 ]Will be assessed by NCI CTCAE. All Treatment or surgically related AEs will be reported descriptively. A proportion of toxicity equal or greater than 3 will be estimated using binomial distribution.
- Inhibition of tumor cell proliferation (KI-67) [ Time Frame: Inhibition of Tumor Cell Proliferation (KI-67) ]
Descriptive statistics will be used for summarizes results and Box plots could be used to present the difference between the treated and untreated groups.
This was more an explorative measure and it was not completed.
- Ex-vivo Sensitivity of Tumor Sphere Cultures to Lapatinib Ditosylate [ Time Frame: Day of surgery ]
The ex-vivo sensitivity of tumor sphere cultures established from surgical specimens to pulsatile lapatinib ditosylate is defined by a minimum of 20% reduction in cell proliferation as measured by cell titer glow in the pulsatile lapatinib ditosylate group compared to the untreated group. Fisher's exact test will be used for testing a difference in the proportion between the two groups.
This was more an explorative measure and it was not completed.
- Objective Response Rate [ Time Frame: Up to 2 years ]Will be estimated along with 95% confidence intervals using the exact binomial method.
- Overall Survival [ Time Frame: From the date of treatment start to the date of death, assessed up to 2 years ]The Kaplan-Meier method will be used to estimate overall survival probability and median time of survival along with a 95% confidence interval.
- Progression-free Survival [ Time Frame: Start of treatment up to 6 months ]The Kaplan-Meier method will be used to estimate progression-free survival probability and median time of survival along with a 95% confidence interval.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have histologically proven World Health Organization (WHO) grade IV glioblastoma/ gliosarcoma or WHO grade III glioma (anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma, anaplastic ependymoma) which is progressive or recurrent following radiation therapy +/- chemotherapy
- Patients must have measurable, supratentorial contrast-enhancing progressive or recurrent high-grade glioma by magnetic resonance imaging (MRI) imaging within 21 days of starting treatment; patient must be able to tolerate MRIs
- Patients may have an unlimited number of prior therapy regimens
-
Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:
- 12 weeks from the completion of radiation
- 6 weeks from a nitrosourea chemotherapy
- 3 weeks from a non-nitrosourea chemotherapy
- 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents
- 4 weeks from the last treatment with bevacizumab
- 2 weeks from administration of a non-cytotoxic, FDA-approved agent other than bevacizumab (e.g., hydroxychloroquine, etc.)
-
Patients must be undergoing surgery that is clinically indicated as determined by their care providers; patients must be eligible for surgical resection according to the following criteria:
- Expectation that the surgeon is able to resect at least 500 mg of tumor from enhancing tumor and 100 mg from non-enhancing tumor with low risk of inducing neurological injury
- Patient tumor sample must have evidence of EGFR gene amplification by fluorescence in situ hybridization (FISH) using a Clinical Laboratory Improvement Act (CLIA)-certified laboratory assay
- Paraffin embedded tissue must be available from initial surgical resection at diagnosis (prior to any treatment)
- Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 9 g/dL
- Total bilirubin =< institutional upper limit of normal
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional upper limit of normal
- Creatinine =< institutional upper limit of normal OR creatinine clearance >= 60 ml/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5 x institutional upper limit of normal
- Patients must have left ventricular ejection fraction (LVEF) within normal institutional limits within 21 days of starting treatment
- Patients must have a 12-lead electrocardiogram performed within 2 weeks of treatment start with corrected (QTC) =< 470 msec
- Patients must be able to provide written informed consent
- Women of childbearing potential must have a negative serum pregnancy test prior to study entry; women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 4 months after completion of lapatinib administration
- Patients must have no concurrent malignancy except curatively treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or bladder; patients with prior malignancies must be disease-free for >= five years
- Patients must be able to swallow medication by mouth, either tablets or dispersed tablets in solution
Exclusion Criteria:
- Patients may not be receiving any other investigational agents
- Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib are ineligible
- Patients with prior therapy with EGFR inhibitors are ineligible because treatment with EGFR kinase inhibitors or other EGFR-targeted agents has the potential to deplete the tumor of EGFR-amplified or EGFR mutant cell populations and confound the evaluation of lapatinib effects on EGFR phosphorylation; patients with prior EGFRvIII vaccine are eligible if recurrent tumor is positive for EGFR gene amplification
- Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic drugs or not be taking any anti-epileptic drugs; patients previously treated with EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the first dose of lapatinib
- Patients must not have evidence of significant hematologic, renal, or hepatic dysfunction
- Patients must not have evidence of significant intracranial hemorrhage
- Patients with uncontrolled intercurrent illness including, but not limited to, hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, are ineligible
- Pregnant women are excluded from this study because lapatinib has potential for teratogenic or abortifacients effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lapatinib, breastfeeding should be discontinued if the mother is treated with lapatinib
- Human immunodeficiency virus (HIV)-positive patients on strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducers or inhibitors are ineligible
- Patients who have acute or currently active/requiring anti-viral therapy hepatic or biliary disease are ineligible (with the exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases from the primary brain tumor, or stable chronic liver disease per investigator assessment)
- Patients receiving P-glycoprotein (P-gp) inhibitors are ineligible
- Patients who are receiving a drug that has a risk of QTc prolongation if QTc is >= 460 msec. are ineligible
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02101905
| United States, California | |
| UCLA / Jonsson Comprehensive Cancer Center | |
| Los Angeles, California, United States, 90095 | |
| United States, Maryland | |
| Johns Hopkins University/Sidney Kimmel Cancer Center | |
| Baltimore, Maryland, United States, 21287 | |
| United States, Massachusetts | |
| Dana-Farber Cancer Institute | |
| Boston, Massachusetts, United States, 02215 | |
| United States, Michigan | |
| Henry Ford Hospital | |
| Detroit, Michigan, United States, 48202 | |
| United States, New Jersey | |
| Memorial Sloan Kettering Basking Ridge | |
| Basking Ridge, New Jersey, United States, 07920 | |
| Memorial Sloan Kettering Monmouth | |
| Middletown, New Jersey, United States, 07748 | |
| United States, New York | |
| Memorial Sloan Kettering Commack | |
| Commack, New York, United States, 11725 | |
| Memorial Sloan Kettering Westchester | |
| Harrison, New York, United States, 10604 | |
| Memorial Sloan Kettering Cancer Center | |
| New York, New York, United States, 10065 | |
| United States, North Carolina | |
| Wake Forest University Health Sciences | |
| Winston-Salem, North Carolina, United States, 27157 | |
| United States, Ohio | |
| Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Pennsylvania | |
| University of Pittsburgh Cancer Institute (UPCI) | |
| Pittsburgh, Pennsylvania, United States, 15232 | |
| Principal Investigator: | Timothy F Cloughesy | National Cancer Institute (NCI) |
Documents provided by National Cancer Institute (NCI):
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT02101905 |
| Other Study ID Numbers: |
NCI-2014-00634 NCI-2014-00634 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) ABTC-1302 ( Other Identifier: Adult Brain Tumor Consortium ) ABTC-1302 ( Other Identifier: CTEP ) U01CA137443 ( U.S. NIH Grant/Contract ) UM1CA137443 ( U.S. NIH Grant/Contract ) |
| First Posted: | April 2, 2014 Key Record Dates |
| Last Update Posted: | April 29, 2024 |
| Last Verified: | April 2024 |
|
Glioblastoma Glioma Astrocytoma Ependymoma Gliosarcoma Oligodendroglioma Brain Neoplasms Recurrence Disease Attributes Pathologic Processes Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms |
Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases Lapatinib Tyrosine Kinase Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |